Erschienen in:
01.03.2009 | Original Article
Repaglinide plus single-dose insulin glargine: a safe regimen for low-risk type 2 diabetic patients who insist on fasting in Ramadan
verfasst von:
Okan Bakiner, Melek E. Ertorer, Emre Bozkirli, Neslihan B. Tutuncu, Nilgun G. Demirag
Erschienen in:
Acta Diabetologica
|
Ausgabe 1/2009
Einloggen, um Zugang zu erhalten
Abstract
Aim of this prospective study is to evaluate the effect of repaglinide t.i.d. (three times a day) plus single-dose insulin glargine regimen in low-risk type 2 diabetic patients during Ramadan fasting. Participants had been taking the regimen for at least 3 months. Patients with a history of diabetic coma, severe hypoglycemic crisis or repeating attacks of hypoglycemia were excluded. Hypoglycemic unawareness, kidney or liver disease or HbA1c over 8% were also accepted as exclusion criteria. Eleven patients who insisted on this worship and eight non-fasting cases were involved. All were told to make home-glucose-monitorisation weekly and report any hypoglycemic event throughout Ramadan. Fasting blood glucose (FBG), post-prandial blood glucose (PBG) and fructosamine levels, body weights and blood pressures were recorded just before and after Ramadan. Seven patients in each group concluded the follow-up. Any significant change was detected in the parameters in either groups (P > 0.05). Glucose control remained unchanged; fructosamine 318.14 ± 65.38 versus 317.28 ± 52.80 mmol/L in fasting group, 290.71 ± 38.48 versus 290 ± 38.56 mmol/L in non-fasting group. None of them exhibited either a major or a minor hypoglycemic event. The results of this pilot study indicated that repaglinide t.i.d. plus single-dose insulin glargine regimen was safe for low-risk type 2 diabetic patients who insisted on fasting during Ramadan.